Perianal Crohn's disease is correlated with a significant decrease in quality of life and can predict unfavorable outcomes. In this condition, it is recommended that a multidisciplinary team including a gastroenterologist, colorectal surgeon and radiologist will be involved to optimize therapeutic decisions. Despite the advent of biologic and surgical therapies, the success rate of therapy is unsatisfactory and may result in a high chance of recurrence. In recent years, novel therapies have been introduced which include local injection of mesenchymal stem cells and surgical techniques which can improve the outcome and quality of life of the patients. The goal of this review, is to raise the awareness and summarize the therapeutic options available for the treatment of perianal Crohn's disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.
BMC Gastroenterol
December 2024
Formerly Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic de Barcelona, Barcelona, Spain.
Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).
View Article and Find Full Text PDFIntestinal Tuberculosis With Recurrent Gluteal Abscesses and Perianal Fistulas: A Case Report and Literature Review.
Cureus
December 2024
Pharmacology, Universidade Federal do Vale do São Francisco, Petrolina, BRA.
This case is relevant for describing a rare presentation of intestinal tuberculosis with perianal manifestations, complicated by abscesses and recurrent fistulas. The clinical manifestations mimicked Crohn's disease and other inflammatory conditions, making the diagnosis challenging and requiring a differentiated and meticulous diagnostic process. A 45-year-old male patient presented with a chronic abscess in the left buttock lasting for two years, characterized by spontaneous purulent drainage and multiple recurrences despite surgical and clinical treatments.
View Article and Find Full Text PDFEarly intervention with Ustekinumab is associated with higher rates of clinical and endoscopic remission in patients with Crohn's disease.
Therap Adv Gastroenterol
December 2024
Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China.
Background: Early biologic intervention after diagnosis has shown improved clinical and endoscopic outcomes in patients with Crohn's disease (CD), while very little is known about the effectiveness of early versus late administration of Ustekinumab (UST).
Objectives: We aimed to compare early versus late UST use in managing CD and identify potential predictors associated with clinical and endoscopic outcomes.
Design: This was a retrospective observational study.
Management of Perianal Fistulas Associated with Crohn Disease: A Nurse's Perspective.
Gastroenterol Nurs
November 2024
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.
Therap Adv Gastroenterol
December 2024
Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani, 2, Padua 35128, Italy.
Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!